News | May 23, 2023
Freenome acquires global immunodiagnostics developer Oncimmune
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
Acquisition enhances Freenome's product portfolio, including autoantibody platform with additional biomarkers important in cancer detection
NDA supported by data from global Phase III FRESCO-2 study in the U.S., Europe, Japan and Australia along with data from Phase III FRESCO study conducted in China
Launch of the Da Vinci Xi Robotic System is the highlight of the Robotic Colorectal Cancer Symposium organized with the Association of Colon and Rectal Surgeons of India
Pfizer’s total cumulative revenue from Seagen therapies is expected to reach $36 billion by 2028, according to GlobalData, a leading data and analytics company.
Twelve hospitals across India will be part of the network which will support the trial in India
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
According to GlobalData’s analyst consensus forecast, OTX-2002 is projected to have the highest revenue by 2028, with sales of $1.6 billion during that year
The product is backed by required scientific proof and comparative bioequivalence studies
This clinical study aims to evaluate the efficacy of JAB-21822 in combination with cetuximab in patients with KRAS G12C-mutated colorectal cancer.
The two-day meeting in the city was organized in collaboration with the University of Birmingham, Christian Medical College Ludhiana, and Birmingham Clinical Trials Unit
Subscribe To Our Newsletter & Stay Updated
